Retail consulting

On April 23, 2026, the U.S. Department of Justice announced a significant regulatory change, moving FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. At the same time, the Drug Enforcement Administration (DEA) restarted a formal rulemaking that could ultimately extend Schedule III treatment more broadly, with hearings scheduled to begin this summer. These actions mark an important step in the federal government’s evolving approach to marijuana regulation. While they do not eliminate all uncertainty, they create immediate tax implications and longer-term planning considerations for businesses operating in or alongside the medical marijuana industry. Here is an overview of the key changes and how they may impact your business: Section 280E no longer applies to medical marijuana prospectively One of the most significant outcomes of rescheduling is the removal of Internal Revenue Code Section 280E for qualifying medical marijuana businesses. For years, Section 280E has prevented marijuana businesses from deducting ordinary and necessary operating expenses due to marijuana’s Schedule I classification. With medical marijuana now classified as Schedule III, state-licensed medical marijuana operators may deduct ordinary business expenses on a go-forward basis. This includes costs such as payroll, rent, utilities, insurance and general administrative expenses that were previously disallowed. The change will materially reduce effective tax rates and improve cash flow. It may also affect estimated tax payments, budgeting, pricing decisions and long-term financial projections. Businesses that have structured operations around 280E limitations should consider revisiting their tax and accounting approach with this shift in mind. Recreational marijuana remains classified as a Schedule I controlled substance and Section 280E will continue to apply. However, businesses with both medical and recreational activities will need clear accounting practices to properly segregate income and expenses and manage ongoing compliance risk. What does the medical marijuana federal rescheduling mean for your business? Federal rescheduling represents an important opportunity for the medical marijuana industry and possibly the marijuana industry at large. While change is underway, regulatory clarity will continue to develop over time. What is clear today: State-licensed medical marijuana is no longer classified as a Schedule I substance. Section 280E no longer applies to qualifying medical marijuana businesses on a prospective basis. Federal agencies are actively pursuing broader rescheduling through formal rulemaking. What remains unresolved: Whether retroactive tax relief will be granted and, if so, how it will be implemented. The timing and structure of IRS transition guidance. The ultimate outcome of the DEA’s proposed rulemaking and related hearings. Thoughtful planning now can help organizations navigate near-term uncertainty while preparing for longer-term shifts in the regulatory and financial landscape. Businesses that take a measured approach, including evaluating opportunities, managing risk and maintaining strong compliance practices, will be better positioned as guidance evolves. Here are three areas your business can address to prepare for changes in the tax landscape: 1. Retroactive tax relief In its announcement, the Department of Justice encouraged the Department of the Treasury, which includes the IRS, to consider whether retroactive relief from Section 280E should be provided for medical marijuana businesses. If implemented, such relief could address prior‑year tax liabilities that arose solely due to 280E or provide retroactive relief for returns with time to amend. At this stage, however, there is no formal IRS guidance outlining how retroactive relief might be applied. The IRS has previously warned taxpayers against filing amended returns based on anticipated regulatory changes. Until clearer direction is issued, businesses should avoid taking independent action that could create unintended compliance or audit risk. Instead, businesses can review historical tax positions, model potential exposure and organize supporting documentation so that they remain prepared if additional guidance becomes available. 2. Implications for banking and financial services Rescheduling medical marijuana to Schedule III also has implications beyond taxation. Schedule I status has long limited access to traditional banking and financial services due to heightened federal compliance concerns. Schedule III classification lowers, but does not eliminate, those perceived risks, particularly for medical marijuana businesses. Over time, this may lead to expanded access to banking relationships, lending options, payroll services and insurance products. Businesses may also see improved capital access and operational flexibility as financial institutions reevaluate their risk tolerance. At the same time, increased access to traditional financial services often comes with higher expectations around financial reporting, documentation and internal controls. Businesses should be prepared for greater scrutiny as relationships with regulated financial institutions mature. 3. Broader financial and strategic planning considerations The removal of 280E for medical marijuana has downstream effects that extend beyond tax compliance. Lower effective tax rates may influence business valuations , debt servicing, expansion planning and transaction activity. Improved access to capital could accelerate growth or consolidation within the industry. It is also important to remember that federal rescheduling does not replace state law. Businesses remain subject to detailed state licensing, compliance and reporting requirements, and federal and state regulatory frameworks will continue to operate alongside one another rather than in complete alignment. Read more: Gross receipts taxes: How could they affect your business? Don’t leave money on the table: 3 tax opportunities that often get missed The Court of Federal Claims just opened a tax relief window